Thomas Karalis News Today

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Antengene has received approval in Hong Kong for a new drug application (NDA) for Xpovio (selinexor) to treat multiple myeloma (R/R MM).

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Indonesia National Agency of Drug and Food...

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ --Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO (selinexor) to the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment ...

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ --Antengene recently unveiled a new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help Antengene to attract more top talents, and further accelerate its expansion in the APAC region as well as its committed efforts to bring high quality and affordable innovative medicines to patient...

In Australia around 2,400 people are diagnosed each year with multiple myeloma (MM), and around 20,000 patients are living with MM at any given time. 

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. -...

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma - read this article along with other careers information, tips and advice on BioSpace

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. These patients have poor prognosis and limited treatment options. - XPOVIO® is the first of a new class...